Kezar Life Sciences Reports Third Quarter 2024 Financial Results …

5 days ago · Net loss for the third quarter of 2024 was $20.3 million, or $2.78 per basic and diluted common share, compared to a net loss of $23.1 million, or $3.18 per basic and diluted …

CouponFollow Extension

$20
OFF

Kezar Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

5 days ago · Net loss for the third quarter of 2024 was $20.3 million, or $2.78 per basic and diluted common share, compared to a net loss of $23.1 million, or $3.18 per basic and diluted …

businesswire.com

$7
OFF

KZR - Kezar Life Sciences Reports Third Quarter 2024...

1 week from now

5 days ago · Research and development (R&D) expenses for the third quarter of 2024 decreased by $7.5 million to $16.2 million, compared to $23.7 million in the third quarter of 2023. This …

marketwirenews.com

$148
OFF

Kezar Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

4 days ago · Kezar Life Sciences reported Q3 2024 financial results and provided updates on its clinical trials. The company's cash position stood at $148.4 million as of September 30, 2024. …

stocktitan.net

$2.80
OFF

Kezar Life Sciences (KZR) Earnings Date And Reports 2024

1 week from now

2 days ago · Kezar Life Sciences posted Q2 2024 earnings on August 13, 2024, reporting an EPS of -$2.80, which topped the consensus estimate of -$3.20 by $0.40. With a trailing EPS of …

marketbeat.com

$20
OFF

Kezar Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

5 days ago · Net loss for the third quarter of 2024 was $20.3 million, or $2.78 per basic and diluted common share, compared to a net loss of $23.1 million, or $3.18 per basic and diluted …

stockhouse.com

$4
OFF

Kezar Life Sciences Reports Second Quarter 2024 Financial Results …

1 week from now

Jun 30, 2024 · Research and development (R&D) expenses for the second quarter of 2024 decreased by $4.7 million to $16.3 million, compared to $21.0 million in the second quarter of …

morningstar.com

52%
OFF

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, …

morningstar.com

52%
OFF

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, …

biospace.com

FAQs about Kezar Life Sciences Reports Third Quarter 2024 Financial Results … Coupon?

When is Kezar life sciences's next earnings date?

Kezar Life Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off prior year's report dates. When is Kezar Life Sciences's earnings date? ...

Who owns Kezar Life Sciences Inc (KZR)?

On October 1, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) made a significant new investment in the biotechnology sector by purchasing 7,200,000 shares of Kezar Life Sciences Inc (NASDAQ:KZR). ...

Who is Kezar life sciences?

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. ...

What is the 12-month price forecast for Kezar life sciences (KZR)?

The 12-month stock price forecast is $20.0, which is an increase of 171.37% from the latest price. NEW YORK-- (BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors' and officers' possible v... ...